Coverage: The Meridian legal market record (editorial).
Territory is described as MENA regionally; no African country is named in the trade coverage available to this run, so the African nexus is regional only.
| Record ID | TX-AFR-2025-0012 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Patent licence, Exclusive licence, In-licensing |
| IP rights | patent, know-how, regulatory data |
| Status | Signed |
| Qualifying date | 2025-10-06 |
| Sector | Life sciences · Pharmaceuticals – biosimilars |
| African markets | Multi-jurisdictional |
| Licensed territory | MENA region. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, single · 1 source(s) |
| Last verified | 2026-10-25 |
Parties
- Hikma Pharmaceuticals PLC (United Kingdom): licensee
- Celltrion Inc. (South Korea): licensor
Key terms
- Interest: exclusive licence; Exclusivity: exclusive; Territorial scope: MENA region
Sources
- Hikma and Celltrion deepen alliance to boost biosimilar access in MENA, PharmaTimes, 2025-10-06
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


